In this Q&A, Ping Moore, OD, covers emerging dry eye therapies, from selenium sulfide to next-gen cyclosporine, and how subtype-guided care shapes treatment choices.
|Videos|August 25, 2020
Kala’s dry eye treatment nears potential US launch before 2021
Author(s)Alex Delaney-Gesing , Sheryl Stevenson
Susan Coultas, PhD, and Preeya Gupta, MD, discuss Kala Pharmaceuticals’ dry eye product candidate in a poster presentation during the 2020 Women in Ophthalmology virtual summer symposium.
Advertisement
Susan Coultas, PhD (top left), and Preeya Gupta, MD (bottom, middle) , discuss Kala Pharmaceuticals’ dry eye product candidate in a poster presentation—“Safety and Efficacy of KPI-121 0.25% for the Short-Term Treatment of Signs and Symptoms of Dry Eye Disease in Three Large Multicenter Randomized Controlled Trials”—during the 2020 Women in Ophthalmology virtual summer symposium with Sheryl Stevenson, group editorial director, Ophthalmology Times®.
Advertisement
Related to this article
Two investigational pipeline therapies take aim at the root causes of dry eye disease
Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.
Ophthalmology is projected to face one of the steepest physician shortages of any subspecialty by 2038.
Dry eye care pivots to root-cause diagnosis and personalized biologics/devices,
Findings from the third annual State of Dry Eye survey link symptom management to quality of life gains, including lower anxiety and improved self-confidence.
Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Comments from the FDA Advisory Committee meeting on SYD-101
2
Q&A: Phentolamine for presbyopia: a non-miotic route to near vision
3
Stool biomarker uncovers silent bowel disease in uveitis patients
4
OT Roundup: 3 FDA approvals, vorolanib insert miss, brepocitinib in uveitis
5